Jordan Metcalf, MD
Critical Care Medicine · Oklahoma City, OKNPI 1376512269
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $623 and has fallen 89.1% since, to $68 in 2024.
Across 36 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$176
- Actelion Pharmaceuticals US, Inc.$152
- GSK$134
- Grifols Shared Services North America, Inc.$68
- Merck$60
- Gilead$51
- plus $125 from 4 others
Across 21 payments — averaging $10,688 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Shared Services North America, Inc.$84K
- Emergent Biosolutions Inc.$58K
- AstraZeneca$29K
- PTC Therapeutics, Inc.$23K
- Chiesi USA, Inc.$19K
- Sage Therapeutics, LLC$11K
What the payments were for
- Food & beverage$765100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 9 | $176 |
| Actelion Pharmaceuticals US, Inc. | 6 | $152 |
| GSK | 8 | $134 |
| Grifols Shared Services North America, Inc. | 1 | $68 |
| Merck | 4 | $60 |
| Gilead | 2 | $51 |
| Novartis | 2 | $43 |
| Vifor Pharma, Inc. | 2 | $41 |
| United Therapeutics Corporation | 1 | $28 |
| Electromed, Inc. | 1 | $13 |
How this compares
$765 in reported general payments places this provider in the 55th percentile of 57 critical care medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in Oklahoma City
- Obaid AshrafOklahoma City$12K
- Michael HarperOklahoma City$6K
- Syed AnwerOklahoma City$4K
- Victoria KyleOklahoma City$4K
- Himanshu BhardwajOklahoma City$3K
- Mark RolfeOklahoma City$3K
- Brent BrownOklahoma City$2K
- Joseph BrewerOklahoma City$2K
- Mircea MihuOklahoma City$2K
- Laura SwantOklahoma City$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.